Mar. 20 at 7:00 PM
$TOVX Q4 '25 Earnings Results & Recap
Theriva expects current cash to fund operations into Q1 2027, but additional capital is needed for future clinical trials, with R&D expenses anticipated to decrease in 2026 due to workforce reduction and strategic focus.